WO2018197736A3 - Composición que comprende mirnas para su uso como medicamento - Google Patents

Composición que comprende mirnas para su uso como medicamento Download PDF

Info

Publication number
WO2018197736A3
WO2018197736A3 PCT/ES2018/070325 ES2018070325W WO2018197736A3 WO 2018197736 A3 WO2018197736 A3 WO 2018197736A3 ES 2018070325 W ES2018070325 W ES 2018070325W WO 2018197736 A3 WO2018197736 A3 WO 2018197736A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
diseases
mirnas
drug
allergies
Prior art date
Application number
PCT/ES2018/070325
Other languages
English (en)
French (fr)
Other versions
WO2018197736A2 (es
Inventor
Michael Hackenberg
Michail Kotsyfakis
Gonzalo MARTINEZ NAVAJAS
Houria BOULAIZ TASSI
Juan Antonio Marchal Corrales
Original Assignee
Universidad De Granada
Biology Centre Of The Czech Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Granada, Biology Centre Of The Czech Academy Of Sciences filed Critical Universidad De Granada
Publication of WO2018197736A2 publication Critical patent/WO2018197736A2/es
Publication of WO2018197736A3 publication Critical patent/WO2018197736A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición que comprende al menos un oligonucleótido derivado de miRNAs de saliva de la garrapata Ixodes ricinus. Dicha composición es útil como método de tratamiento de un trastorno seleccionado entre cánceres, enfermedades inflamatorias, alergias, dermatitis atópica, lupus, asma, dolor crónico, trastornos relacionados con el ritmo circadiano, enfermedades metabólicas, diabetes, glaucoma, hepatitis, enfermedades cardiovasculares, Parkinson, enfermedades neurológicas y neurodegenerativas y epilepsia.
PCT/ES2018/070325 2017-04-24 2018-04-24 Composición que comprende mirnas para su uso como medicamento WO2018197736A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201730635A ES2688970A1 (es) 2017-04-24 2017-04-24 Composición que comprende mirnas para su uso como medicamento.
ESP201730635 2017-04-24

Publications (2)

Publication Number Publication Date
WO2018197736A2 WO2018197736A2 (es) 2018-11-01
WO2018197736A3 true WO2018197736A3 (es) 2019-01-03

Family

ID=63920279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2018/070325 WO2018197736A2 (es) 2017-04-24 2018-04-24 Composición que comprende mirnas para su uso como medicamento

Country Status (2)

Country Link
ES (1) ES2688970A1 (es)
WO (1) WO2018197736A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227777A1 (en) * 2019-05-16 2020-11-19 Monash University Method for promoting autophagy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131356A1 (en) * 2006-09-19 2009-05-21 Asuragen, Inc. miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090163435A1 (en) * 2006-09-19 2009-06-25 Bader Andreas G miR-200 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131356A1 (en) * 2006-09-19 2009-05-21 Asuragen, Inc. miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090163435A1 (en) * 2006-09-19 2009-06-25 Bader Andreas G miR-200 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARRERO ROBERTO A ET AL.: "Evolutionary conserved microRNAs are ubiquitously expressed compared to tick-specific miRNAs in the cattle tick Rhipicephalus (Boophilus) microplus", BMC GENOMICS, vol. 12, 24 June 2011 (2011-06-24), pages 1 - 17, XP021102707, ISSN: 1471-2164 *
HACKENBERG MICHAEL ET AL.: "In silico target network analysis of novo-discovered, tick saliva-specific microRNAs reveals important combinatorial effects in their interference with vertebrate host physiology", RNA, vol. 23, no. 8, 31 July 2017 (2017-07-31), pages 1259 - 1269, XP055560523, ISSN: 1355-8382 *
MIN HYEYOUNG ET AL.: "Got target?: computational methods for microRNA target prediction and their extension", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 42, no. 4, 31 March 2010 (2010-03-31), pages 233 - 244, XP055560519, ISSN: 1226-3613 *
SCHWARZ ALEXANDRA ET AL.: "A Systems Level Analysis Reveals Transcriptomic and Proteomic Complexity in Ixodes Ricinus Midgut and Salivary Glands During Early Attachment and Feeding", MOLECULAR & CELLULAR PROTEOMICS, vol. 13, no. 10, 30 September 2014 (2014-09-30), pages 2725 - 2735, XP055560516, ISSN: 1535-9476 *
ZHOU JINLIN ET AL.: "Distinctive microRNA profiles in the salivary glands of Haemaphysalis longicornis related to tick blood-feeding", EXPERIMENTAL AND APPLIED ACAROLOGY, vol. 59, no. 3, March 2003 (2003-03-01), pages 339 - 349, XP055560509, ISSN: 0168-8162 *

Also Published As

Publication number Publication date
WO2018197736A2 (es) 2018-11-01
ES2688970A1 (es) 2018-11-07

Similar Documents

Publication Publication Date Title
EP3934736A4 (en) PORTABLE PERIPHERAL NERVE STIMULATION FOR THE TREATMENT OF DISEASES THROUGH RHYTHMIC BIOLOGICAL PROCESSES
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
MX2016002644A (es) Composicion que comprende torasemida y baclofeno para tratar trastornos neurologicos.
PH12019502254A1 (en) Methods and systems for modulating stimuli to the brain with biosensors
EA201891224A1 (ru) Способы и системы для предоставления стимулов для головного мозга
PH12018502028A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
MX340568B (es) Terapia para transtornos neurologicos a base de baclofeno y acampros ato.
WO2017075338A3 (en) Delivery of central nervous system targeting polynucleotides
WO2012006419A3 (en) Pro-neurogenic compounds
NZ700374A (en) New therapeutic approaches for treating parkinson’s disease
NZ773177A (en) Neuroactive steroid formulations and methods of treating cns disorders
EA201991375A1 (ru) Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
MX2015017169A (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
WO2012012772A3 (en) Drug eluting hydrogels for catheter delivery
TW200635589A (en) Therapeutic agents
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
WO2014093230A3 (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP3856168A4 (en) COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISEASES
SA519410296B1 (ar) أجهزة إشعاع عبر الجلد واستخدامها في علاج الأمراض التَنَكُّسِيٌّة العَصَبِيّة
EP3573616A4 (en) NEW INHIBITOR OF SPIRO AND CYCLIC BIS-BENZYLIDINE PROTEASOME FOR THE TREATMENT OF CANCER, DIABETES AND NEUROLOGICAL DISORDERS
WO2018197736A3 (es) Composición que comprende mirnas para su uso como medicamento
IN2013DN11328A (es)
HK1252981A1 (zh) 作為用於治療數種疾病如抑鬱症、糖尿病和帕金森病的taar調節劑的吡唑甲酰胺衍生物
UA98133C2 (en) Therapeutic use of eslicarbazepine
MX2016000724A (es) Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18790468

Country of ref document: EP

Kind code of ref document: A2